Reimbursement / E-health - Kesimpta
Kesimpta ® is reimbursed in Belgium for adult patients with clinically proven relapsing multiple sclerosis (RMS) who meet the following criteria* :
The patient has a fast evolving, serious form of relapsing multiple sclerosis (RMS...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
Kesimpta ® is a targeted and precisely delivered B-cell therapy 1,5B-cells play a central role in the pathogenesis of MS 4
KESIMPTA ® (ofatumumab) is a fully human anti...
Twitter Linkedin Facebook Pinterest Google plusAdministration & Dosing
Patient Resources - Kesimpta
Indication
FABHALTA ® is indicated as monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have haemolytic anemia 1 .
FABHALTA® is the first and only Factor B inhibitor. FABHALTA® acts...
Twitter Linkedin Facebook Pinterest Google plusClinical efficacy & safety
The efficacy and safety 5 of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
The most commonly reported adverse reactions were upper respiratory tract infection (18.9%), headache (18.3%) and diarrhoea (11.0%). The most commonly reported serious adverse reaction was urinary tract infection (1.2%) 1,4 .Twitter Linkedin Facebook Pinterest Google plusReimbursement
Mechanism of Action (MoA)
Mechanism of Action (MoA)¹
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...
Twitter Linkedin Facebook Pinterest Google plus
